Role of immunosuppression regimen in post-transplant lymphoproliferative disorder in pediatric heart transplant patients
Jeffrey D Dayton, Marc E Richmond, Robert G Weintraub, Anne T Shipp, Manuela Orjuela, Linda J Addonizio
The Journal of Heart and Lung Transplantation | ELSEVIER SCIENCE INC | Published : 2011
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) contributes to morbidity and mortality after transplantation. We examined the effect of immunosuppressive regimen on the risk of developing PTLD after pediatric heart transplantation. METHODS: The 324 pediatric heart transplant patients at 2 children's hospitals were retrospectively reviewed for the primary outcome of PTLD development. Patient demographics, rejection frequency, serum cyclosporine and tacrolimus levels, induction therapy, donor and recipient Epstein-Barr virus, and cytomegalovirus serologic status were reviewed and comparisons made between immunosuppressive regimens. Comparisons were also made between transplanta..View full abstract
Awarded by National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)
Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES
The authors thank Roger Vaughan, PhD, and Jimmy Duong, MSc, of the Department of Biostatistics, Mailman School of Public Health, for their statistical support, which was supported by Grant Number KL2 RR024157 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at NCRR Web site (http://www.ncrr.nih.gov/). Information on Re-engineering the Clinical Research Enterprise can be obtained from NIH Roadmap Web site (http://nihroadmap.nih.gov/clinicalresearch/).